source
- AbbVie eyes pan-RAS market with up to $1.45 B option to acquire KestrelAbbVie announced it has signed an agreement that gives it the right to acquire Kestrel Therapeutics for up to $1.45 billion. The deal would give AbbVie access to Kestrel’s pipeline focused on pan-…
- BridgeBio's heart drug Attruby exceeds sales expectations, shifting investor outlookBridgeBio prepared to sell its heart drug Attruby on its own, prompting skepticism from investors and analysts who doubted the company could compete with larger rivals. The drug far outperformed f…